[go: up one dir, main page]

DK1124568T3 - Polyspecifikke bindingsmolekyler og anvendelser deraf - Google Patents

Polyspecifikke bindingsmolekyler og anvendelser deraf

Info

Publication number
DK1124568T3
DK1124568T3 DK99970601T DK99970601T DK1124568T3 DK 1124568 T3 DK1124568 T3 DK 1124568T3 DK 99970601 T DK99970601 T DK 99970601T DK 99970601 T DK99970601 T DK 99970601T DK 1124568 T3 DK1124568 T3 DK 1124568T3
Authority
DK
Denmark
Prior art keywords
binding molecules
polyspecific binding
chain
molecules
polyspecific
Prior art date
Application number
DK99970601T
Other languages
Danish (da)
English (en)
Inventor
Hing C Wong
Jon A Weidanz
Kimberlyn Card
Linda A Sherman
Norman R Klinman
Original Assignee
Altor Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience Corp filed Critical Altor Bioscience Corp
Application granted granted Critical
Publication of DK1124568T3 publication Critical patent/DK1124568T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK99970601T 1998-10-21 1999-10-21 Polyspecifikke bindingsmolekyler og anvendelser deraf DK1124568T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10516498P 1998-10-21 1998-10-21
PCT/US1999/024645 WO2000023087A1 (fr) 1998-10-21 1999-10-21 Molecules de liaison polyspecifiques et leurs utilisations

Publications (1)

Publication Number Publication Date
DK1124568T3 true DK1124568T3 (da) 2008-01-02

Family

ID=22304401

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99970601T DK1124568T3 (da) 1998-10-21 1999-10-21 Polyspecifikke bindingsmolekyler og anvendelser deraf

Country Status (9)

Country Link
US (3) US6534633B1 (fr)
EP (1) EP1124568B1 (fr)
JP (1) JP4467188B2 (fr)
AT (1) ATE370967T1 (fr)
AU (1) AU1218000A (fr)
DE (1) DE69936927T2 (fr)
DK (1) DK1124568T3 (fr)
ES (1) ES2293748T3 (fr)
WO (1) WO2000023087A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144474A1 (en) * 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
JP4447456B2 (ja) 2001-06-05 2010-04-07 アルトール バイオサイエンス コーポレーション P53結合t細胞受容体分子とその使用
EP1567553A2 (fr) * 2002-12-03 2005-08-31 Avidex Ltd. Recepteurs
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
US7964380B2 (en) * 2005-01-21 2011-06-21 Argylia Technologies Nanoparticles for manipulation of biopolymers and methods of thereof
GB0507046D0 (en) * 2005-04-06 2005-05-11 Celltech R&D Ltd Primers
US20080299137A1 (en) * 2005-10-28 2008-12-04 Novo Nordisk A/S Fusion Proteins That Bind Effector Lymphocytes And Target Cells
WO2007085266A1 (fr) * 2006-01-30 2007-08-02 Dako Denmark A/S Quantification ultra-rapide de lymphocytes-t spécifiques d'antigènes dans du sang entier par cytométrie de flux
EP2505209A1 (fr) 2006-06-26 2012-10-03 MacroGenics, Inc. Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US20100210478A1 (en) * 2006-06-29 2010-08-19 Xiaolian Gao Make and use of surface molecules of varied densities
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
EP2167537A2 (fr) 2007-07-03 2010-03-31 Dako Denmark A/S Procedes compiles pour analyser et trier des echantillons
WO2009039854A2 (fr) 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US20110070191A1 (en) * 2008-03-19 2011-03-24 Wong Hing C T cell receptor fusions and conjugates and methods of use there of
WO2009151514A1 (fr) * 2008-06-11 2009-12-17 Millipore Corporation Bioréacteur à cuve agitée
CN104800147A (zh) * 2008-07-10 2015-07-29 德勒尼克斯治疗股份公司 用于大分子的增强的递送的方法和组合物
WO2010009735A2 (fr) * 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
ES2749232T3 (es) * 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
EP2258719A1 (fr) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Récepteur de lymphocyte T à cibles multiples
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SG10201804385YA (en) 2010-05-17 2018-06-28 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
KR20130041843A (ko) * 2010-06-08 2013-04-25 이엠디 밀리포어 코포레이션 바이오 분자의 정제에 사용되는 중합체의 잔량을 검출하는 방법
AU2012316859A1 (en) * 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
DK3369742T3 (da) 2011-10-05 2020-10-19 Univ Rockefeller Dimere bakteriofaglysiner
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP2802356A1 (fr) 2012-01-13 2014-11-19 Apo-T B.V. Immunoglobulines restreintes à une cellule aberrante dotées d'une fraction toxique
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3071594A4 (fr) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Récepteurs modifiés de haute affinité pour les lymphocytes t humains
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Car t細胞療法のための方法および組成物
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
EP3579870A4 (fr) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Agents de ciblage de tumeur à lymphocytes t car (ctct) d'éther de phospholipide (ple)
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
WO2018160622A1 (fr) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions et méthodes de thérapie par lymphocytes t car
WO2018166589A1 (fr) 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Récepteurs d'antigènes et leurs utilisations
WO2019046818A1 (fr) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Peptides immunogènes spécifiques des antigènes bcma et taci pour le traitement du cancer
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院(Dba西雅图儿童研究所) 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
CA3090236A1 (fr) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Polytherapie de cancer impliquant des proteines de liaison multi-specifiques qui activent des cellules tueuses naturelles
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
WO2019165237A1 (fr) 2018-02-23 2019-08-29 Endocyte, Inc. Procédé de séquençage pour thérapie par lymphocytes t à car
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
CA3131138A1 (fr) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Recepteurs de lymphocytes t specifiques de l'antigene de maturation des lymphocytes b pour le traitement du cancer
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2022187539A1 (fr) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Méthodes de traitement du cancer à l'aide de protéines de liaison multi-spécifiques qui se lient à nkg2d, à cd16 et à un antigène associé à une tumeur
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
IL321737A (en) * 2023-01-05 2025-08-01 Angeles Therapeutics Inc Methods and compositions for gene transformation and control of activity of synthetic and immune receptors
GB202320012D0 (en) * 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2098368T3 (es) 1990-08-09 1997-05-01 Nat Jewish Ct Immun & Respirat Produccion de anticuerpos monoclonales contra un elemento vbeta humano de los receptores de las celulas t, utilizando vectores de adn recombinante.
AU643109B2 (en) * 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
CA2118508A1 (fr) 1992-04-24 1993-11-11 Elizabeth S. Ward Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
WO1996018105A1 (fr) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
JPH11507843A (ja) * 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
ATE533784T1 (de) * 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors

Also Published As

Publication number Publication date
ATE370967T1 (de) 2007-09-15
DE69936927D1 (de) 2007-10-04
JP4467188B2 (ja) 2010-05-26
JP2004537952A (ja) 2004-12-24
WO2000023087A1 (fr) 2000-04-27
US8105830B2 (en) 2012-01-31
EP1124568B1 (fr) 2007-08-22
US6534633B1 (en) 2003-03-18
DE69936927T2 (de) 2008-05-15
ES2293748T3 (es) 2008-03-16
EP1124568A1 (fr) 2001-08-22
US20030171552A1 (en) 2003-09-11
US20120230995A1 (en) 2012-09-13
EP1124568A4 (fr) 2003-08-27
AU1218000A (en) 2000-05-08

Similar Documents

Publication Publication Date Title
DK1124568T3 (da) Polyspecifikke bindingsmolekyler og anvendelser deraf
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
CY1110579T1 (el) Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου
ATE276275T1 (de) Mhc-komplexe und ihre verwendungen
ATE187494T1 (de) Multivalente einkettige antikörper
CY1112101T1 (el) Νευροτροφικοι παραγοντες
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
NO20100580L (no) Fremgangsmater for behandling av reumatoid artritt ved anvendelse av opploselig mutant CTLA4 molekyl
DE60219419D1 (de) Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
NO961706D0 (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
DE69942981D1 (de) Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
NO981745L (no) Monoklonalt antistoff BR110 og anvendelse av dette
DK1479696T3 (da) Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi
MY112916A (en) A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
ATE505208T1 (de) Rezeptorbindende konjugate
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
EP1071443A4 (fr) Peptides isoles correspondant a des sequences d'acides amines de ny-eso-1 qui se lient a des molecules mhc de classe i et mhc de classe ii, et leurs utilisations
WO2003106649A3 (fr) Test d'un conjugue et ses utilisations
NO20053304L (no) NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse
DK1121594T3 (da) Fremgangsmåder til identifikation af hot-spot remanenser af bindende proteiner og små forbindelser som binder til samme
NO20022441L (no) Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
EA200400384A1 (ru) Растворимый рецептор т-клетки